A study of NVX-108 (Perflenapent) in patients with hypoxic solid brain tumor, glioblastoma multiforme (GBM).

Trial Profile

A study of NVX-108 (Perflenapent) in patients with hypoxic solid brain tumor, glioblastoma multiforme (GBM).

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Perflenapent (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 According to National Cancer Institute media release, National Cancer Institute (NCI) has awarded a grant for up to $3 million to NuvOx Pharma to initiate this trial.
    • 28 Aug 2017 According to a NuvOx Pharma media release, this trial will be led by Dr. Baldassarre Stea from the University of Arizona. The trial will be conducted at Banner MD Anderson, Banner-University Medical Center Tucson, Barrow Neurological Institute and Miami Cancer Institute.
    • 18 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top